Effect of endocrine therapies on bone in breast cancer patients

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages 308-319

  Santen, Richard J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTRADIOL; ESTROGEN; EXEMESTANE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STRONTIUM; TAMOXIFEN; TAMOXIFEN CITRATE; ZOLEDRONIC ACID; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BONE DENSITY CONSERVATION AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADD ON THERAPY; BONE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL DECISION MAKING; DRUG MECHANISM; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; FRACTURE; FRACTURE REDUCTION; FRAGILITY FRACTURE; HUMAN; KNOWLEDGE; LOW DRUG DOSE; MEDICAL LITERATURE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARIAN SUPPRESSION; OVARY FUNCTION; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TUMOR GROWTH; ADULT; AGED; BONE DEVELOPMENT; BONE DISEASE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; BONE DISEASES; BONE RESORPTION; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; FRACTURES, BONE; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANK LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 79951710902     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1679     Document Type: Review

References (88)

1. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA; Z-FAST and ZO-FAST Study Groups 2008 Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514 (Pubitemid 351872868)
2. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet [Erratum (2007) 369:906] 369:559-570
3. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R 2006 Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol [Erratum (2007) 8:6] 7:991-996 (Pubitemid 44804137)
4. Boccardo F, Rubagotti A, Aldrighetti D, Buzzi F, Cruciani G, Farris A, Mustacchi G, Porpiglia M, Schieppati G, Sismondi P 2007 Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. Cancer 109:1060-1067 (Pubitemid 46435383)
5. Brown SA, Guise TA 2009 Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr 19:47-60
6. Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA 2006 Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7:127-132 (Pubitemid 44044008)
7. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ 2010 American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796
8. Reifenstein Jr EC, Albright F 1947 The metabolic effects of steroid hormones in osteoporosis. J Clin Invest 26:24-56
9. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH, Endocrine Society 2010 Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95(7 Suppl 1):S1-S66
10. Torgerson DJ, Bell-Syer SE 2001 Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2:7
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333 (Pubitemid 34761611)
12. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B 1998 Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339:733-738 (Pubitemid 28417356)
13. Cauley JA, LaCroix AZ, Robbins JA, Larson J, Wallace R, Wactawski-Wende J, Chen Z, Bauer DC, Cummings SR, Jackson R 2010 Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial. Osteoporos Int 21:167-177
14. Klein KO, Demers LM, Santner SJ, Baron J, Cutler Jr GB, Santen RJ 1995 Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 80:2658-2660
15. Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, Gabet Y 2010 Regulation of adult bone turnover by sex steroids. J Cell Physiol 224:305-310
16. Khosla S 2008 Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. Bone 43:414-417
17. Khosla S 2010 Update on estrogens and the skeleton. J Clin Endocrinol Metab 95:3569-3577
18. Venken K, Callewaert F, Boonen S, Vanderschueren D 2008 Sex hormones, their receptors and bone health. Osteoporos Int 19:1517-1525
19. Tomkinson A, Reeve J, Shaw RW, Noble BS 1997 The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128-3135 (Pubitemid 27385687)
20. Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S 2007 Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72:666-671 (Pubitemid 46977432)
21. Bundred NJ 2009 Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol 21:60-67
22. Naessen T, Berglund L, Ulmsten U 1997 Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol. Am J Obstet Gynecol 177:115-119 (Pubitemid 27327321)
23. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, Vittinghoff E, Grady D 2004 Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104:443-451 (Pubitemid 40458828)
24. Sapi E, Brown WD, Aschkenazi S, Lim C, Munoz A, Kacinski BM, Rutherford T, Mor G 2002 Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Investig 9:243-250 (Pubitemid 34756803)
25. Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F 2000 Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73:185-194
26. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S 2007 Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell 130:811-823 (Pubitemid 47332572)
27. Pacifici R 2008 Estrogen deficiency, T cells and bone loss. Cell Immunol 252:68-80
28. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R 2001 Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 98:13960-13965 (Pubitemid 33116006)
29. Hawse JR, Subramaniam M, Ingle JN, Oursler MJ, Rajamannan NM, Spelsberg TC 2008 Estrogen-TGFβ cross-talk in bone and other cell types: role of TIEG, Runx2, and other transcription factors. J Cell Biochem 103:383-392 (Pubitemid 351171910)
30. Hawse JR, Subramaniam M, Monroe DG, Hemmingsen AH, Ingle JN, Khosla S, Oursler MJ, Spelsberg TC 2008 Estrogen receptor β isoform-specific induction of transforming growth factor β-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol Endocrinol 22:1579-1595 (Pubitemid 351920392)
31. Pfeilschifter J, Köditz R, Pfohl M, Schatz H 2002 Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23:90-119 (Pubitemid 34185307)
32. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230 (Pubitemid 36519939)
33. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370 (Pubitemid 30647136)
34. Lindberg MK, Erlandsson M, Alatalo SL, Windahl S, Andersson G, Halleen JM, Carlsten H, Gustafsson JA, Ohlsson C 2001 Estrogen receptor α, but not estrogen receptor β, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-κB ligand) ratio and serum interleukin-6 in male mice. J Endocrinol 171:425-433 (Pubitemid 34026357)
35. Rudnik V, Sanyal A, Syed FA, Monroe DG, Spelsberg TC, Oursler MJ, Khosla S 2008 Loss of ERE binding activity by estrogen receptor-α alters basal and estrogen-stimulated bone-related gene expression by osteoblastic cells. J Cell Biochem 103:896-907 (Pubitemid 351240625)
36. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2007 Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285-27297 (Pubitemid 47501960)
37. Di Gregorio GB, Yamamoto M, Ali AA, Abe E, Roberson P, Manolagas SC, Jilka RL 2001 Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17 β-estradiol. J Clin Invest 107:803-812 (Pubitemid 32274033)
38. Manolagas SC 2000 Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137 (Pubitemid 32275592)
39. van der Eerden BC, Löwik CW, Wit JM, Karperien M 2004 Expression of estrogen receptors and enzymes involved in sex steroid metabolism in the rat tibia during sexual maturation. J Endocrinol 180:457-467 (Pubitemid 38443398)
40. Janssen JM, Bland R, Hewison M, Coughtrie MW, Sharp S, Arts J, Pols HA, van Leeuwen JP 1999 Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J Cell Biochem 75:528-537 (Pubitemid 29521659)
41. Yanase T, Suzuki S, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H 2003 Aromatase in bone: roles of vitamin D3 and androgens. J Steroid Biochem Mol Biol 86:393-397 (Pubitemid 37412577)
42. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A 2009 History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 30:343-375
43. Ghosh D, Griswold J, Erman M, Pangborn W 2009 Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 457:219-223
44. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' group 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
45. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group 2006 Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223
46. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G 2007 Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25:2664-2670 (Pubitemid 47123171)
47. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147 (Pubitemid 46224022)
48. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271 (Pubitemid 41535367)
49. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J Clin Oncol 24:3629-3635 (Pubitemid 46630537)
50. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492
51. Jones S, Stokoe C, Sborov M, Braun M, Ethirajan S, Kutteh L, Pippen J, Patel M, Paul D, Blum JL, Holmes FA, Myron MC, Cantrell J, Hartung NL, Look RM, Di Salle E, Davis JC, Ilegbodu D, Asmar L 2008 The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin Breast Cancer 8:527-532
52. Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R 2007 Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40:205-210 (Pubitemid 44839329)
53. Vogel VG 2001 Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res 7(12 Suppl):4413s-4418s; discussion 4411s-4412s
54. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462 (Pubitemid 41111693)
55. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC, Intergroup Exemestane Study group 2007 Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncology 8:119-127 (Pubitemid 46158372)
56. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53
57. Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A 2009 The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 18:159-164
58. Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J 2006 Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 42:2968-2975 (Pubitemid 44667475)
59. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD 2007 Estrogen-dependent increase in bone turnover and bone loss in postmenopausalwomenwith breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41:346-352 (Pubitemid 47199159)
60. Hadji P 2009 Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73-82
61. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662 (Pubitemid 41672231)
62. Gail MH 2001 The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann NY Acad Sci 949:286-291 (Pubitemid 34059992)
63. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V 1999 Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst [Erratum (2000) 92:275] 91:1829-1846
64. McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R 2007 Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 43:2523-2531 (Pubitemid 350086940)
65. McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM 2010 A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 119:643-651
66. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R 2008 Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849
67. Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE 2004 Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694-3699 (Pubitemid 41095208)
68. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Brown JE, Hannon RA, Coleman RE 2008 Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342
69. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R 2010 Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967-975
70. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA 2009 Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85
71. Brufsky A, Harker G, Beck JT, Carroll R, Jin L, Warsi G, Argonza-Aviles E, Ericson S, Perez EA The effect of zoledronic acid on aromatase inhibitor-associated bone loss in premenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5 year final follow up. San Antonio Breast Cancer Symposium, San Antonio, TX, 2009 (Abstract 4083)
72. Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D 2010 Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Gynecol Oncol 117:139-145
73. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D 2009 Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118:81-87
74. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882
75. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, Moore DH, Rugo HS 2008 Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 26:15S (Abstract 559)
76. Rack B, Schindlbeck C, Strobl B, Sommer H, Friese K, Janni W 2008 [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study (in German)]. Deutsche Medizinische Wochenschrift 133:285-289 (Pubitemid 351315392)
77. Solomayer ER, Gebauer G, Hirnle P, Janni W, L̈uck H, Becker S, Huober J, Kraemer B, Wackwitz B, Fehm T 19 February 2009 Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 10.1158/0008-5472.SABCS-2048
78. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K 2010 Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11:421-428
79. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, Marth C 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med [Erratum (2009) 360:2379] 360:679-691
80. Coleman R, Bundred NJ, DeBoer R, Llombarto A, Campbell L, Neven P, Barrios C, Dias R, Miller J, Brufsky A Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST San Antonio Breast Cancer Symposium, San Antonio, TX, 2009 (Abstract 4082)
81. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F 2008 Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19:2007-2011
82. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J 2006 Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 8:R13
83. Saarto T, Blomqvist C, Virkkunen P, Elomaa I 2001 Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10-17 (Pubitemid 32063474)
84. Ha TC, Li H 2007 Meta-analysis of clodronate and breast cancer survival. Br J Cancer 96:1796-1801 (Pubitemid 46912011)
85. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S; American Society of Clinical Oncology 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol [Erratum (2004) 22:1351] 21:4042-4057
86. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE 2008 Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(Suppl 1):S3-S18
87. Gralow JR, Bierman JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH 2009 NCCN task force report: bone health in cancer cancer care. J Natl Compr Can Netw 7(Suppl 2):S1-S32
88. Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M 2008 Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407-1416